SLGL חוב כולל להון Sol-Gel Technologies, Ltd.

Sol-Gel Technologies (SLGL) maintains a high reputation in dermatology due to its innovative component encapsulation method. This chart reflects a price trend demonstrating a total debt-to-equity ratio of 0.02. Sol-Gel Technologies (SLGL) sustains business stability through patent protection and efficient pharmacy sales. Meanwhile, the company strictly adheres to ESG principles by implementing energy-saving technologies and the safe recycling of chemical waste.

This ratio correlates total liabilities with equity, determining the extent of the company's reliance on debt financing to support its operational activities. By analyzing the historical debt-to-equity ratio, an investor can assess how conservatively Sol-Gel Technologies (SLGL) finances its drug microencapsulation developments to ensure that innovations in dermatology do not become hostages to an excessive credit burden.